Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas

作者: Tammy Sung , Douglas C. Miller , Roberta L. Hayes , Michelle Alonso , Herman Yee

DOI: 10.1111/J.1750-3639.2000.TB00258.X

关键词:

摘要: Classification of high grade astrocytomas children into genetic subtypes similar to the adult remains be defined. Here we report an extensive characterization 29 pediatric astrocytomas, 7 WHO III and 22 IV, for alterations frequently observed in occurring either p53/MDM2/p14ARF or Rb/CDK4/p16INK4a tumor suppressor pathways. In addition, have assessed contribution EGFR overexpression amplification LOH chromosome 10, two commonly associated with development de novo glioblastoma their roles childhood. Our results suggest major differences pathway(s) leading formation compared those adult. findings show preferential inactivation p53 pathway > 95% versus Rb < 25% same tumors. lack gene one-third glioblastomas. Since drug treatments therapy strategies exploit specific cells, our important implications future astrocytomas.

参考文章(51)
X.-D. Yang, A. Jakobovits, Ping Wang, C. G. Davis, X.-C. Jia, J. R. F. Corvalan, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. ,vol. 59, pp. 1236- 1243 ,(1999)
Andreas von Deimling, Jimmy T. Efird, John W. Henson, David N. Louis, Yasuhiro Ono, Keisuke Ueki, CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated Cancer Research. ,vol. 56, pp. 150- 153 ,(1996)
Gollin Sm, Pollack If, Hamilton Rl, Campbell Jw, Finkelstein Sd, Sherwin Rn, Bozik Me, Martinez Aj, The Relationship between TP53 Mutations and Overexpression of p53 and Prognosis in Malignant Gliomas of Childhood Cancer Research. ,vol. 57, pp. 304- 309 ,(1997)
David K. Moscatello, Albert J. Wong, Gloria Ramirez, A Naturally Occurring Mutant Human Epidermal Growth Factor Receptor as a Target for Peptide Vaccine Immunotherapy of Tumors Cancer Research. ,vol. 57, pp. 1419- 1424 ,(1997)
Samar Jasser, W. K.Alfred Yung, Amy Berson, Diana Iliev, Carmen Tornos, Gregory Fujii, Gordon B. Mills, Lee Ellis, Marsha Frazier, Lauren A. Langford, Peter A. Steck, Thaylon Davis, Brad Swedlund, Patricia Troncoso, Cheryl Frye, David H.F. Teng, Raphael E. Pollack, Kipp L. Hansen, Rong Hu, Mark A. Pershouse, Jeff Lee, Adel El-Naggar, Robert Bookstein, Kathryn L. Gumpper, Huai Lin, Scan V. Tavtigian, Vickie L. Vinson, Joseph B. Bolen, MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Research. ,vol. 57, pp. 5221- 5225 ,(1997)
R Godbout, J He, MJ Allalunis-Turner, rd Rs Day, VP Collins, JR Allen, CD James, CDK4 Amplification Is an Alternative Mechanism to p16 Gene Homozygous Deletion in Glioma Cell Lines Cancer Research. ,vol. 54, pp. 5804- 5807 ,(1994)
Richard M. Cawthon, Carolyn A. Pedone, Douglas Brockmeyer, Dan Fults, Micam W. Tullous, p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Research. ,vol. 52, pp. 674- 679 ,(1992)
Guido Reifenberger, Ghazaleh Tabatabai, Marietta Wolter, J. M. J. Ludwig Cobbers, V. Peter Collins, Peter Lichter, Ruthild G. Weber, Jan Boström, Mutation of the PTEN (MMAC1) Tumor Suppressor Gene in a Subset of Glioblastomas but not in Meningiomas with Loss of Chromosome Arm 10q Cancer Research. ,vol. 58, pp. 29- 33 ,(1998)
Nikolai G. Rainov, Karl-Ulrich Dobberstein, Hannes Bahn, Hans-Jürgen Holzhausen, Christine Lautenschläger, Volkmar Heidecke, Winfried Burkert, Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival Journal of Neuro-oncology. ,vol. 35, pp. 13- 28 ,(1997) , 10.1023/A:1005841520514
Paul Cairns, David Sidransky, Janusz Puc, Jeffrey N. Bruce, Steven I. Wang, Ramon Parsons, Jing Li, Somatic mutations of PTEN in glioblastoma multiforme. Cancer Research. ,vol. 57, pp. 4183- 4186 ,(1997)